3. PFWD data for comparisons of pentoxifylline versus other treatments.

Study	Dose	Dur	Pxt	Oth	Px0	SD	Px‐E	SD	%age	Oth0	SD	Oth‐E	SD	%age	Diff
Bohmer 1988 Gingko biloba	1200	24	13	14	80.1		325.6		306.5	94.6		327.5		246.2	60.3
Chacon‐Quevedo 1994 Buflomedil	1200	13	15	15	109	63	194	72	78.0	97	73	160	73	64.9	13.1
Chacon‐Quevedo 1994 Nifedipine	1200	13	15	15	109	63	194	72	78.0	109	56	194	65	78.0	0
Creager 2008* Iloprost	1200	24	86	87					34.3					31.2	3.1
Dawson 2000 Cilostazol	1200	24	232	227	126	79	202	139	60.3	124	81	218	149	75.8	‐15.5
Hepp 1992 PGE1	400	4	98	97	72		133		84.7	80		175		118.8	‐34.1
Perhoniemi 1984 Flunarizine cross‐over	1200	12	31	31	135		160		18.5	135		16		19	0
Schellong 2012 PGE1	1200	8	285	276			1.98**	3.61				2.60**	12.22

*highest dose group iloprost.
 **PFWD reported as ratio of distance after 8 weeks of treatment compared with baseline.

Dur: duration in weeks.
 Pxt: pentoxifylline sample size.
 Oth: other treatment group sample size.
 Px0: baseline walking distance in meters for pentoxifylline group.
 SD: standard deviation.
 Px‐E: end walking distance in meters for pentoxifylline group.
 %age: percentage improvement in walking distance.
 Oth0: baseline walking distance in meters for other treatment group.
 Oth‐E: end walking distance in meters for other treatment group.
 Diff: difference in percentage improvement for pentoxifylline and other treatment groups.